文献速递前列腺癌

前列腺特异性抗原密度用于选择磁共振成像靶向活检与联合活检诊断前列腺癌:Trio研究的二次分析

Prostate-Specific Antigen Density to Select Magnetic Resonance Imaging-Targeted vs Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study.
PubMed 文献 · J Urol · 2025-02-14

该二次分析纳入PSA升高和/或直肠指检异常且MRI可见前列腺病灶的男性,评估PSAD在联合活检中对临床显著前列腺癌检出的辅助预测价值。随PSAD区间升高,联合活检检出GG≥3癌的比例约翻倍;PSAD≥0.2 ng/mL/cm3时系统活检额外检出临床显著癌的比例低(2%,95%CI 0.4%-5.9%)。作者认为临床医生可考虑对PSAD≥0.2 ng/mL/cm3者省略系统活检。

要点

  • PSAD<0.1、≥0.1且<0.15、≥0.15且<0.2、≥0.2 ng/mL/cm3时GG≥3癌检出率分别约9.3%、18.2%、36%、61.2%。
  • PSAD≥0.2 ng/mL/cm3时系统活检额外检出临床显著癌仅2%(95%CI 0.4%-5.9%)。
  • 作者认为临床医生可考虑对PSAD≥0.2 ng/mL/cm3的MRI可见病灶仅行靶向活检。

核心结论

  • 随PSAD区间升高,联合活检检出GG≥3癌的比例约翻倍,临床医生可考虑用PSAD对临床显著前列腺癌高风险男性进行风险分层。
  • 对PSAD≥0.2 ng/mL/cm3的MRI可见病灶患者,临床医生可考虑省略系统活检而仅行靶向活检,因系统活检额外检出临床显著癌的比例低。

研究设计与样本

  • Trio研究的二次分析,纳入PSA升高和/或直肠指检异常且MRI可见前列腺病灶的男性,行MRI靶向活检与系统活检。
  • 主要结局为按4个PSAD区间(<0.1、≥0.1且<0.15、≥0.15且<0.2、≥0.2 ng/mL/cm3)分别计算的MRI靶向活检、系统活检和联合活检的临床显著前列腺癌检出率。
  • 次要结局为系统活检相对于单独MRI靶向活检的附加价值。

主要发现

  • 在PI-RADS≥2病灶的男性中,随PSAD超过各区间,GG≥3癌检出率约翻倍:<0.1为9.3%,≥0.1且<0.15为18.2%,≥0.15且<0.2为36%,≥0.2为61.2%。
  • PSAD≥0.2 ng/mL/cm3时,系统活检额外检出临床显著癌的比例低(2%,95%CI 0.4%-5.9%)。

关键数值与推荐

  • PSAD区间划分:<0.1、≥0.1且<0.15、≥0.15且<0.2、≥0.2 ng/mL/cm3。
  • PSAD≥0.2 ng/mL/cm3时系统活检额外检出临床显著癌为2%(95%CI 0.4%-5.9%)。

临床怎么用

  • 作者认为临床医生可考虑用PSAD对临床显著前列腺癌高风险男性进行风险分层。
  • 作者认为对PSAD≥0.2 ng/mL/cm3的MRI可见病灶患者,临床医生可考虑省略系统活检而仅行靶向活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The addition of systematic prostate biopsy enhances the detection of clinically significant prostate cancer compared with MRI-targeted biopsy alone. However, there is growing interest in using only MRI-targeted biopsy. We sought to evaluate PSA density (PSAD) as an adjunctive predictor of clinically significant prostate cancer detection in men undergoing combined biopsy and as a potential metric to stratify which patients may reasonably avoid systematic biopsies in favor of MRI-targeted biopsy only. MATERIALS AND METHODS: Men with elevated PSA and/or abnormal digital rectal examination found to have an MRI-visible prostate lesion underwent MRI-targeted and systematic prostate biopsy. Primary outcomes were clinically significant cancer detection rates by MRI-targeted, systematic biopsy, and combined biopsy across 4 discrete PSAD intervals (<0.1, ≥0.1 and <0.15, ≥0.15 and <0.2, and ≥0.2 ng/mL/cm3). Secondary outcomes were the added value of systematic biopsy relative to MRI-targeted biopsy alone. RESULTS: Among men with Prostate Imaging Reporting and Data System ≥ 2 lesions, as PSAD surpassed each interval, the rate of grade group ≥ 3 cancer detection approximately doubled (<0.1: 9.3%, ≥0.1 and <0.15: 18.2%, ≥0.15 and <0.2: 36%, and ≥0.2: 61.2%). For PSAD ≥ 0.2, added detection of clinically significant cancer with systematic biopsy was low (2%, 95% CI: 0.4%-5.9%). CONCLUSIONS: Given an approximate doubling in grade group ≥ 3 cancer detection on combined biopsy with rising PSAD intervals, clinicians may consider PSAD in risk stratifying men at high risk of clinically significant prostate cancer. Clinicians may consider omitting systematic biopsy for targeted biopsy of MRI-visible lesions in patients with PSAD ≥ 0.2 ng/mL/cm3, as systematic biopsy results in low rates of additional clinically significant cancer detection.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ahdoot M, Naser-Tavakolian A, Heard JR, et al. Prostate-Specific Antigen Density to Select Magnetic Resonance Imaging-Targeted vs Combined Biopsy for Prostate Cancer Diagnosis: A Secondary Analysis of the Trio Study. J Urol. 2025. PMID: 39951686. doi:10.1097/JU.0000000000004480

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。